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Abstract
Recent generation of patient-specific induced pluripotent stem cells (PS-iPSCs) provides significant advantages for
cell- and gene-based therapy. Establishment of iPSC-based therapy for skin diseases requires efficient methodology
for differentiating iPSCs into both keratinocytes and fibroblasts, the major cellular components of the skin, as well as
the reconstruction of skin structures using these iPSC-derived skin components. We previously reported generation
of keratinocytes from human iPSCs for use in the treatment of recessive dystrophic epidermolysis bullosa (RDEB)
caused by mutations in the COL7A1 gene. Here, we developed a protocol for differentiating iPSCs into dermal
fibroblasts, which also produce type VII collagen and therefore also have the potential to treat RDEB. Moreover, we
generated in vitro 3D skin equivalents composed exclusively human iPSC-derived keratinocytes and fibroblasts for
disease models and regenerative therapies for skin diseases, first demonstrating that iPSCs can provide the basis for
modeling a human organ derived entirely from two different types of iPSC-derived cells.
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Introduction
Induced pluripotent stem cells (iPSCs) are stem cells
generated from individual somatic cells by exogenous
expression of several transcription factors to initiate the
reprogramming process [1]. In recent years, patient-specific
iPSCs (PS-iPSCs) have been derived from patients with
several human diseases to investigate unknown disease
mechanisms and perform pre-clinical testing in various models
[2]. Autologous PS-iPSCs have the potential to provide an
unlimited source of cells for gene and cell therapies for specific
human diseases, since they are believed to have unlimited
proliferative capacity and extensive differentiation capability
into a wide range of cell types.
Recessive dystrophic epidermolysis bullosa (RDEB) is an
inherited blistering disorder caused by mutations in the
COL7A1 gene encoding type VII collagen, the major
component of anchoring fibrils at the basement membrane
zone (BMZ) at the epidermal-dermal junction of the skin. Since
anchoring fibrils provide functional integrity to the skin,
defective anchoring fibrils caused by lack or deficiency of type
VII collagen leads to skin fragility. Therefore, patients with
RDEB develop severe skin phenotypes, including repeated
skin blistering from minor trauma, as well as mutilating
scarring, alopecia, corneal erosions, tooth and nail dystrophy,
esophageal strictures, joint contractures, and fusion of fingers
and toes [3]. RDEB patients also present an increased risk of
developing squamous cell carcinomas (SCCs) in early
adulthood as a result of repeated and aberrant wound repair
and chronic inflammation. Furthermore, since SCCs in patients
with RDEB are highly aggressive and metastatic, SCCs are
one of the most life-threatening complications for RDEB
patients [4].
There is currently no cure for RDEB. One promising strategy
for RDEB treatment is to increase the amount of type VII
collagen at the epidermal-dermal junction in patients with
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RDEB to restore skin integrity [5]. Various trials are being
pursued using gene-, protein-, drug- and cell-based
approaches to address this challenge. Although keratinocytes
produce the majority of collagen VII in the skin in vivo, several
studies using mouse models and mouse/human fibroblasts
have shown that dermal fibroblasts also synthesize type VII
collagen, suggesting that both cell types are potentially useful
as a source of cells for treating RDEB [6–10]. Previous clinical
studies have shown that a single intradermal injection of
allogeneic fibroblasts led to increased expression of type VII
collagen at the epidermal-dermal junction in patients with
RDEB [10]. Although donor fibroblasts were undetectable in
recipient skin 2 weeks after injection, the newly produced type
VII collagen persisted for 3 months, suggesting that cell-based
approaches that introduce exogenous type VII collagen-
producing cells, such as fibroblasts, might have a therapeutic
benefit.
We previously reported the generation of PS-iPSCs from
patients with RDEB and efficient derivation of functional
keratinocytes from normal and RDEB PS-iPSCs, thereby
demonstrating the utility of PS-iPSCs for establishing cell- and
gene-based therapy for RDEB [11]. In contrast, the
methodology for generating dermal fibroblasts from ESCs/
iPSCs has not yet been fully defined. Therefore, the goal of this
study was to establish proof-of-principle for differentiating
iPSCs into dermal fibroblasts with high efficiency to provide a
new source of cells for RDEB treatment, and further to develop
3D skin equivalents derived exclusively from human iPSCs.
Results
Derivation of Fibroblasts from Human iPSCs
We first aimed to develop a differentiation protocol to
generate dermal fibroblasts from iPSCs in vitro. In previous
studies, ESCs have been differentiated into mesodermal
lineages using several methods and reagents. Ascorbic acid is
well known to induce mesodermal differentiation of ESCs
[12,13] and increase collagen synthesis [14], and is widely
used to generate mesodermal components from ESCs [15,16].
Moreover, it has been reported that members of the TGFβ
family can also enhance not only mesodermal differentiation
from stem cells [17–19], but also collagen production in
somatic cells, including fibroblasts [20,21]. In particular, TGFβ2
has been reported to involve in epithelial-to-mesenchymal
transition in several contexts [22,23]. Other studies also
demonstrated that embryoid body formation could lead to
spontaneous differentiation of ESCs, and provide fibroblast-like
spindle-shaped cells with the capability to maintain ESC
pluripotency as feeder cells [24–26].
Based on such studies, we generated embryoid bodies from
iPSCs to initiate differentiation, and used medium
supplemented with ascorbic acid and TGFβ2 to accelerate
mesodermal differentiation to generate fibroblasts from iPSCs
(Figure 1A). As a result, we observed fibroblast-like spindle-
shaped cells outgrowing from attached embryoid bodies, and
relatively uniform population of fibroblast-like cells was
obtained after several passages (Figure 1B).
Characteristics of iPSC-Derived Fibroblasts
We next examined the characteristics of iPSC-derived cells
to define their fibroblast-like properties. We confirmed by RT-
PCR that stem cell markers, OCT4 and SOX2, had completely
disappeared in iPSC-derived cells after differentiation. In
addition, the expression of several markers indicative of
mesodermal and fibroblast induction were strongly detected
(CD73 and type I collagen) or increased (CD10 and type III
collagen. These markers were also weakly expressed in ESC
(data not shown)) in iPSC-derived cells (Figure 1C). We
compared the expression of fibroblast-associated CD surface
markers, CD10, CD44, CD73 and CD90, between normal
human fibroblasts and iPSC-derived fibroblasts by FACS.
These markers were found in greater than 90% of iPSC-
derived fibroblasts (CD10: 93.9±2.8%, CD44: 95.9±2.7%,
CD73: 94.1±1.9%, CD90: 96.3±1.9% (n=3)), and their
expression patterns in iPSC-derived fibroblasts were consistent
with those of dermal fibroblasts (Figure 2A).
Moreover, we confirmed by immunostaining that vimentin, a
classic marker of the mesodermal lineage, and prolyl-4-
hydroxylase beta (P4HB), another marker of fibroblasts, were
expressed in iPSC-derived fibroblasts (Figure 2B). P4H,
consisting of two alpha and beta subunits (P4HB), is a
multifunctional enzyme that belongs to the protein disulfide
isomerase family. It plays an essential role in the synthesis of
all collagens by fibroblasts, since it is required for hydroxylation
of prolyl residues in preprocollagens [27]. Consequently, our
data demonstrate that iPSC-derived fibroblasts expressed
Figure 1.  Directed differentiation of iPSCs into
fibroblasts.  (A) Schematic representation of the differentiation
strategy for generating fibroblasts from iPSCs. Cells growing
out from attached embryoid bodies made in medium
supplemented with AA and TGFβ2 were repeatedly split to
obtain a fibroblast-like cell population. (B) Morphology of iPSC-
derived fibroblasts. After 5 passages, fibroblast-like spindle-
shape cells were observed. (C) Gene expression in iPSC-
derived fibroblasts. Expression of stem cell markers (OCT4 and
SOX2) disappeared, and markers of fibroblasts (CD10, CD73,
type I and III collagen) were increased in iPSC-derived
fibroblasts compared with iPSCs.
doi: 10.1371/journal.pone.0077673.g001
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multiple types of collagens, specifically types I, III, IV and VII,
which are hallmarks of normal dermal fibroblasts (Figure 2B).
Capability of iPSC-Derived Fibroblasts to Synthesize
Type VII Collagen
To further interrogate the utility of iPSC-derived fibroblasts
for the treatment of RDEB, we next asked whether these cells
produced and secreted mature type VII collagen, which would
be required to reconstitute anchoring fibrils in the skin of
patients with RDEB. Western blot analysis detected a 290kD
band of type VII collagen in secreted media from iPSC-derived
fibroblasts, as well as from normal human fibroblasts (Figure
2C). The lower band may be the result of degradation or an
immature form of type VII collagen, because it appears to be
more abundant in the cells than in the culture media. This data
demonstrated that iPSC-derived dermal fibroblasts have the
capability to produce and secrete mature type VII collagen
polypeptides.
Skin Reconstitution Using iPSC-Derived Fibroblasts
We next performed skin reconstitution chamber assays to
test the in vivo functional capacity of iPSC-derived fibroblasts.
We found that iPSC-derived fibroblasts combined with normal
human keratinocytes grafted in the chamber contributed to
reconstitution of normal skin structures on the back of SCID
mice, similar to normal human fibroblasts and keratinocytes
(Figure 3). Skin appendages, such as hair follicles and glands,
were not detected, and no cyst or tumor formation was
observed in the grafted sites. In addition, we confirmed that
type VII collagen was expressed at the BMZ of the
reconstituted skin (Figure 3C). The epidermal differentiation
markers, keratin 1 and loricrin, were also expressed in the
upper layers of the epidermis (Figure 3D and 3E), indicating
that keratinocytes grown together with on iPSC-derived
fibroblasts can be functionally and terminally differentiated.
These data suggest that iPSC-derived fibroblasts have the
capacity to support keratinocytes to constitute a multilayered
epidermal structure and BMZ in in vivo reconstituted skin.
Figure 2.  Characteristics of iPSC-derived fibroblasts.  (A) Cell surface marker expression in iPSC-derived fibroblasts. FACS
analysis showed that the cell surface marker profile of iPSC-derived fibroblasts was very similar to normal human fibroblasts, with
over 90% expression of each marker. (B) Protein expression of iPSC-derived fibroblasts. Immunostaining demonstrated that iPSC-
derived fibroblasts express fibroblast markers vimentin (VIM) and prolyl-4-hydroxylase beta (P4HB), and produced multiple types of
collagen as well as normal human fibroblasts. (C) Detection of mature form of type VII collagen. Western blotting analysis detected
290kD bands in each lane, indicating that type VII collagen was synthesized from iPSC-derived fibroblasts, as well as from normal
fibroblasts. The lower band of 250kD may be from either degradation or an immature form of type VII collagen, since it appears to
be more abundant in the cells (lanes 3 and 4) than in the culture media (lanes 1 and 2).
doi: 10.1371/journal.pone.0077673.g002
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Figure 3.  Generation of reconstituted skin using iPSC-derived fibroblasts.  (A) iPSC-derived fibroblasts can contribute to
forming normal skin structures in vivo, comparable to normal human fibroblasts. Staining with an anti-human nuclear antibody
(green signal) clearly shows the presence of human cells on the back skin of the mice. The white arrow indicates the border of the
human cells on the back skin of mouse. Red: keratin 14. Green: human nuclei. Blue: DAPI (both human and mouse nuclei). (B)
Desmoglein 3 is expressed though the epidermis. Green: human desmoglein 3 (does not recognize mouse desmoglein 3). Blue:
DAPI. Dotted line: BMZ. (C) Human type VII collagen (using LH7.2 antibody which is specific for human type VII collagen) is
observed at the BMZ of reconstituted skin using iPSC-derived fibroblasts. Red: keratin 14. Green: human type VII collagen (not
mouse). Blue: DAPI. (D) Keratin 1 is present only in the suprabasal layer of epidermis. Green: human keratin 1 (does not recognize
mouse keratin 1). Blue: DAPI. (E) Loricrin, a terminal differentiation marker of keratinocytes, is observed in the upper layer of
epidermis. Red: loricrin. Green: human nuclei. Blue: DAPI.
doi: 10.1371/journal.pone.0077673.g003
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Generation of 3D Skin Equivalents Using iPSC-Derived
Keratinocytes and Fibroblasts
As a final step toward the future clinical use of iPSC-derived
keratinocytes and fibroblasts, we next generated in vitro 3D
skin equivalents using iPSC-derived cells in both components.
iPSC-derived keratinocytes formed a multilayered epidermis
and cornified layer at the surface of the epidermis on a dermis
consisting of iPSC-derived fibroblasts, similar to those using
normal human keratinocytes and fibroblasts (Figure 4). The
presence of parakeratosis and the lack of a granular layer most
likely occur as a general finding during the generation of 3D
skin, since this was observed in both samples. These data
further support the hypothesis that iPSC-derived fibroblasts can
support the process of keratinocyte stratification, and that
iPSCs have the capability to independently provide full-
thickness artificial skin which contain both an epidermis and a
dermis.
Discussion
The discovery of iPSCs has had a profound impact on the
field of stem cell research and regenerative medicine. In
particular, the generation of PS-iPSCs is expected to provide
an autologous source of cells to develop patient-specific
customized cell and gene therapy [2], in large part by coupling
this approach with gene correction. The methodology for
correcting gene mutations in PS-iPSCs and directly
differentiating iPSCs into skin cells is a critical step toward
enabling the development of iPSC-based cell and gene therapy
for skin diseases. The capability to correct pathogenic
mutations in PS-iPSCs represents a critical advance for basic
biomedical research and a significant step toward iPSC-based
cell replacement therapies.
Recent studies provided the first demonstrations of gene
modification based on homologous recombination in ESCs and
iPSCs using zinc-finger nucleases (ZFNs), a novel tool for
gene modification which generates double-strand breaks at
specific sites in the human genome [28]. Moreover, based on
these studies, successful gene targeting has been reported in
PS-iPSCs from some human monogenetic diseases [29–31].
For example, Yusa et al. showed that transduction of ZFNs in
human iPSCs generated from an individual with α1-antitrypsin
deficiency achieved correction of a point mutation in the α1-
antitrypsin gene that underlies this deficiency. These authors
also confirmed that genetic correction in human iPSCs restored
the structure and function of α1-antitrypsin in subsequently
derived liver-like cells [29], indicating that the combination of a
genome editing technique such as ZFNs, and more recently
transcription activator-like effector nucleases (TALENs) [32],
together with iPSC technology can provide a generalizable
approach to the treatment of monogenic diseases, including
any of the types of EB.
Although homologous recombination-based gene correction
in PS-iPSCs from a skin disease has been not yet reported,
there has recently been progress made in differentiation of
iPSCs into skin cells. For example, our group previously
demonstrated that human iPSCs could be differentiated into
epidermal keratinocytes, one of main components of the skin
[11]. We confirmed the functionality of iPSC-derived
keratinocytes by assessing contribution to in vitro 3D skin
formation and terminal differentiation capability in 3D skin
models [11]. These studies demonstrated crucial proof-of-
principle establishing the potential of iPSCs to generate
autologous donor cells and subsequently keratinocytes for cell-
based therapies for skin diseases.
Here, we report the direct differentiation capability of iPSCs
into fibroblasts, the second predominant cellular component of
the skin. The cells have the capability to treat individuals with
RDEB via their production of type VII collagen, and are also
able to reconstitute full-thickness skin for regenerative therapy.
In addition, fibroblasts may have another role in patients with
RDEB in addition to merely supporting epidermal structure from
the dermis. Although the mechanisms leading to the
Figure 4.  Generation of 3D skin equivalent.  3D skin equivalents were successfully generated using iPSC-derived keratinocytes
and fibroblasts, and are histologically comparable to those generated using normal human keratinocytes and fibroblasts. H & E
staining revealed normal epidermal and dermal morphology, as well as stratification and terminal differentiation.
doi: 10.1371/journal.pone.0077673.g004
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development of aggressive SSCs in RDEB patients is not well
understood, loss of type VII collagen at the BMZ has been
reported to increase the invasive behavior of RDEB-related
SCCs [33]. A recent study showed that type VII collagen
controls the expression level of dermal extracellular matrices
(ECMs) derived from fibroblasts, not from keratinocytes [34,35],
and that the reduction in these ECMs promotes RDEB-related
SCC keratinocyte invasion. Moreover, these authors
demonstrated that re-expression of type VII collagen in RDEB
fibroblasts can reduce tumor cell invasion in 3D skin culture
and restrict tumor growth in vivo [35], indicating that fibroblasts
may potentially be more valuable than keratinocytes as a
potential cell source for RDEB treatment, both to suppress
SCC metastasis, as well as restore BMZ integrity.
Previous studies have reported generation of fibroblasts from
ESCs/iPSCs [36–38], however, these original protocols were
not optimized specifically for generation of fibroblasts from
ESCs/iPSCs. Instead, these methods simultaneously
differentiated ESCs/iPSCs into a heterogeneous mix of
differentiated cell populations, including both fibroblasts and
epithelial cells, because of the use of keratinocyte medium and
feeder cells which are required for keratinocyte culture, as well
as the addition of bone morphogenetic protein 4 which is used
for generating keratinocytes and other epithelial cells from
ESCs/iPSCs [39,40]. Moreover, production of type VII collagen
from fibroblasts derived by these protocols was not previously
demonstrated [38].
Here, we focused on developing a method of specifically
deriving fibroblasts from human iPSCs. Our protocol advances
the generation of fibroblasts for future clinical use, because it
can directly generate a relatively pure fibroblast population
from iPSCs with high efficiency, based on cell surface marker
analysis by FACS (Figure 3). There remains the possibility that
this population may be heterogeneous, since it is difficult to
completely define the characteristics of fibroblasts isolated from
skin dermis, however, it is markedly enriched for fibroblasts.
Additionally, our protocol is quite simple and we found that
iPSC-derived fibroblasts generated in this manner can actively
proliferate at least until passage 10.
Type VII collagen matures via a polymerization process and
the formation of tripeptide structures to generate collagen
fibers. Therefore, using immunostaining and western blot
analysis, we detected the tripeptide form of type VII collagen in
medium cultured from fibroblasts derived from iPSCs by our
protocol, demonstrating that our iPSC-derived fibroblasts had
the capability to produce and secrete fully mature type VII
collagen for the advancement of cell therapy for RDEB.
We next interrogated the in vivo function of iPSC-derived
fibroblasts. Skin reconstitution chamber assays clearly showed
that iPSC-derived fibroblasts can reconstruct human skin
structures in vivo with normal human keratinocytes (Figure 3).
Moreover, positive staining of type VII collagen was observed
at the BMZ of the reconstituted skin, indicating that iPSC-
derived fibroblasts normally have two main in vivo functions of
fibroblasts, not only to generate dermal structure and support
keratinocytes to form a stratified epidermal structure, but also
to form the BMZ along with keratinocytes.
Taken together with our previous study for generating
keratinocytes from iPSCs [11], we have succeeded in
generating the two main cellular components of the skin.
Moreover, we also developed an in vitro autologous basic 3D
skin equivalent entirely reconstituted from iPSC-derived skin
cells. To our knowledge, this is the first report to mimic a simple
human organ in vitro, using two different lineages of cells
derived from human iPSCs, albeit without skin appendages,
vascularization or innervation. Our findings provide an innovate
option for in vitro disease modeling and genetic and stem cell
therapy for skin diseases, including RDEB, as well as different
forms of EB and the other monogenic skin disorders. This
approach will be particularly powerful when combined with
methods to correct the underlying gene mutations in PS-iPSCs,
and/or by generating PS-iPSCs from spontaneously gene-
corrected revertant mosaic skin in which restoration of protein
production has naturally occurred by spontaneous second-site
mutations, which are observed in keratinocytes of patients with
EB [41].
In conclusion, we report a new and efficient methodology for
differentiating human iPSCs into fully functional dermal
fibroblasts, which can synthesize mature type VII collagen to
treat RDEB. Furthermore, we succeeded in generating full-
thickness artificial skin using iPSC-derived keratinocytes and
fibroblasts. Our study indicates that iPSCs have the potential to
supply a source of both major types of skin cells, and produce
an autologous 3D skin equivalent for generating in vitro skin
disease models and developing gene and stem cell therapy for
both inherited skin diseases, as well as more common




We previously generated iPSC lines from human fibroblasts
as previously described [11]. iPS1 and iPS2 in Figure 2 were
different cell lines generated from fibroblasts isolated from a
normal individual. iPSCs were maintained on a mitomycin C
(MMC)-treated mouse embryonic fibroblast (MEF) feeder layer
in medium for iPSC (iPSM: Knockout (KO)-DMEM
supplemented with 20% KO-Serum Replacement, 1%
GultaMax-I, 1% nonessential amino acid, 1% penicillin-
streptomycin (Invitrogen) and 4ng/ml basic fibroblast growth
factor (bFGF) (R&D systems).
iPSC Differentiation into Fibroblasts and Keratinocytes
In order to directly differentiate iPSCs into fibroblasts, we first
generated embryoid bodies (cell aggregates of ESCs/iPSCs)
[1] in iPSM without bFGF, and supplemented with 0.3 mM
ascorbic acid (Sigma-Aldrich), 10ng/ml transforming growth
factor beta2 (TGFβ2) (R&D systems) and ITS-A supplement
(diluted as manufacturer's instruction) (Invitrogen) on a low-
binding dish. For inducing cell outgrowth, embryoid bodies
were attached to a gelatin-coated dish, and cultured in DMEM
(with high glucose) (Invitrogen) supplemented with ascorbic
acid and 20% bovine serum for 10 days. Cells that grew out
Generation of iPSC-Derived 3D Skin Equivalents
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from embryoid bodies were passaged and cultured every week
to obtain consistent spindle-shaped cells (Figure 1A and C).
iPSC-derived keratinocytes used in this study were
generated by a modification of our protocol as previously
described [11]. Briefly, small clumps of iPSCs were subcultured
on Matrigel (BD Biosciences) in MEF-conditioned iPSM for 1
day. iPSCs were incubated in defined keratinocyte serum-free
medium (DKSFM; Invitrogen) supplemented with 1 μM all-trans
retinoic acid (Sigma) and 10 ng/mL bone morphogenetic
protein 4 (BMP4; R&D Systems) for 4 days. Medium was
changed to CnT-07 (CELLnTECH), and differentiated iPSCs
were maintained in culture until 30 days for expansion and
maintenance of iPSC-derived keratinocytes.
RT-PCR and PCR
RNA was extracted using the RNeasy Mini kit (Qiagen) and
DNA was removed by DNase treatment (Invitrogen) to avoid
genomic DNA amplification. Complementary DNA was
synthesized using total 2µg RNA by Superscript III reverse
transcriptase and Oligo(dT) primer (Invitrogen) according to the
manufacturer's instructions. PCR reactions were performed
with Platinum® PCR SuperMix (Invitrogen). All primer
sequences are supplied in Table S1.
FACS Analysis
The differentiated spindle-shape cells were enzymatically
collected and fixed with 4% PFA/PBS for 5 minutes at RT. After
PBS wash, cells were blocked in PBS with 10% goat serum.
Primary antibodies conjugated with fluorescent molecules
(Table S2) were incubated for 1 hour in PBS with 1% goat
serum. Normal IgG and no primary antibody were used as
negative controls. Stained cells were analyzed on BD LSRII
Cell Analyzer using BD FACSDiva software (BD Biosciences)
in order to calculate the differentiation efficiency of iPSCs into
fibroblasts, and to determine the surface characteristics of
iPSC-derived fibroblasts (n=3).
Immunofluorescence Staining
iPSC-derived fibroblasts were fixed with acetone/ethanol.
After one hour of blocking using 10% goat or donkey serum in
PBS, samples were incubated for one hour at room
temperature (RT) or overnight at 4°C with primary antibodies.
After three rinses with PBS, incubation with appropriate
secondary antibodies was performed for 1 hour at RT. To
detect human nuclear staining, frozen sections were fixed with
4% PFA in PBS, and performed blocking process using the
M.O.M. immunodetection kit (Vector Laboratories) according to
the manufacturer's instructions. Human nuclear antibody and
secondary antibody were diluted with M.O.M. diluent and
applied. Nuclear staining was performed by Vectashield®,
mounting medium containing DAPI (Vector Laboratories).
Confocal microscopy (Carl Zeiss LSM 5 Exciter) was used to
visualize and capture immunostained cells with good
resolution. All antibodies are supplied in Table S2.
Western Blot Analysis
In order to collect secreted type VII collagen from FBs and
iPSC-FBs, subconfluent cell cultures were fed for 48 hours with
serum-free medium supplemented with 50 ug/ml ascorbic acid.
For SDS-PAGE analysis, the culture medium was treated with
Amicon Ultra-100,000 Centrifugal Filter Devices (Millipore) for
concentration and desalting. The samples were separated on a
5% polyacrylamide gel under reducing conditions.
Immunoblotting analysis was performed using a rabbit
polyclonal antibody against Collagen Type VII (Calbiochem) at
1:5,000 dilution. After overnight incubation at 4 degrees, the
blot was washed with PBS with Tween 20 for 4 times, 15 min
each at RT and then incubated with the goat anti-rabbit
secondary antibody (1:10,000) and detected with the
SuperSignal West Dura substrate following the manufacturer's
instructions (Thermo Scientific).
Skin Reconstitution Chamber Assay
A sterile silicone chamber (Renner GmbH, Germany) was
implanted into the back of SCID mice under anesthesia to
prevent inward migration of cells from the adjacent skin. Ten
million cells were prepared for each epidermal component
(normal human keratinocytes) and dermal component (normal
human fibroblasts or iPSC-derived fibroblasts), and mixed
together followed by centrifugation. The resultant cell pellet,
comprised of epidermal and dermal cells, was resuspended in
PBS and deposited into the chamber. One week after placing
cells, the silicone chamber was removed. Skin was harvested
from the chamber sites 21 days later to observe reconstituted
skin structures (n=2: In the first experiment, the mouse skin
cells migrated over the grafted area, and overgrew. The results
of the second experiment are shown.).
Generation of 3D Skin Equivalent
3D skin equivalents were generated according to a
previously described protocol [42]. Briefly, a type I collagen
matrix (containing normal human fibroblasts isolated from
foreskin, or iPSC-derived fibroblasts) was deposited onto
polyethylene terephthalate membranes (BD Biosciences), and
allowed to polymerize. After incubation of the polymerized
matrix for 5–7 days, normal human keratinocytes or iPSC-
derived keratinocytes were re-seeded on the matrix, and
incubated for 6 days. The composite culture was raised to the
air-liquid interface and fed from below to induce epidermal
differentiation. 3D skin equivalents were harvested 7 days later
(n=8).
Supporting Information
Table S1.  List of primers used in this study.
(DOCX)
Table S2.  List of antibodies used in this study.
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